These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38763866)

  • 21. Production of biofilm by Staphylococcus aureus: Association with infective endocarditis?
    Alonso B; Pérez-Granda MJ; Latorre MC; Sánchez-Carrillo C; Bouza E; Muñoz P; Guembe M
    Enferm Infecc Microbiol Clin (Engl Ed); 2022 Oct; 40(8):418-422. PubMed ID: 36195405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
    Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
    Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
    Smith JR; Roberts KD; Rybak MJ
    Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.
    Wilson W; Taubert KA; Gewitz M; Lockhart PB; Baddour LM; Levison M; Bolger A; Cabell CH; Takahashi M; Baltimore RS; Newburger JW; Strom BL; Tani LY; Gerber M; Bonow RO; Pallasch T; Shulman ST; Rowley AH; Burns JC; Ferrieri P; Gardner T; Goff D; Durack DT;
    J Am Dent Assoc; 2008 Jan; 139 Suppl():3S-24S. PubMed ID: 18167394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
    Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
    BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.
    Wilson W; Taubert KA; Gewitz M; Lockhart PB; Baddour LM; Levison M; Bolger A; Cabell CH; Takahashi M; Baltimore RS; Newburger JW; Strom BL; Tani LY; Gerber M; Bonow RO; Pallasch T; Shulman ST; Rowley AH; Burns JC; Ferrieri P; Gardner T; Goff D; Durack DT; ; ; ; ;
    J Am Dent Assoc; 2007 Jun; 138(6):739-45, 747-60. PubMed ID: 17545263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of ceftaroline fosamil in the treatment of bacteremia and infectious endocarditis].
    Almirante B; Pericás JM; Miró JM
    Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():44-53. PubMed ID: 24702979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
    Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
    Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
    Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
    Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
    Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
    J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant
    Scutera S; Sparti R; Comini S; Menotti F; Musso T; Cuffini AM; Allizond V; Banche G
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of biofilm by Staphylococcus aureus: Association with infective endocarditis?
    Alonso B; Pérez-Granda MJ; Latorre MC; Sánchez-Carrillo C; Bouza E; Muñoz P; Guembe M
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Apr; ():. PubMed ID: 33867187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases.
    Hitzenbichler F; Mohr A; Camboni D; Simon M; Salzberger B; Hanses F
    Infection; 2021 Feb; 49(1):181-186. PubMed ID: 32965641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
    Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
    Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.